Search results
Results from the WOW.Com Content Network
Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug delivery systems to biotechnology. . The company's drugs reach 70 countries [22] with a footprint that covers advanced markets such as USA, Europe, Japan, [23] Australia as well as emerging markets including India, the Philippines and South Africa to name a
Nearly a week after Lupin Pharmaceuticals announced a voluntary recall of two types of blood pressure medications, the company continues to see its stock price slide (though the hit could have ...
Another pharmaceutical company is recalling a blood pressure medication that could increase the risk of cancer if taken in large amounts. On Wednesday, Lupin Pharmaceuticals recalled four lots of ...
Gupta joined Lupin in 1993, [3] and became CEO in 2013. Gupta was the chairman and CEO of Lupin Pharmaceuticals Inc, from 2003 to 2013, and grew the US business from 5% to over 45% of Lupin's total turnover. [2] The US is Lupin's largest market. [citation needed] Lupin's estimated annual cost savings to the US health system is approximately $15 ...
Desh Bandhu Gupta (8 February 1938 – 26 June 2017) was an Indian billionaire, philanthropist, entrepreneur and the founder of Lupin Limited, a multinational pharmaceutical company. At the time of his death, his net worth was estimated at US$3.6 billion. [1]
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
He is the only son of Desh Bandhu Gupta, who founded Lupin in 1968. [3] His eldest sister, Vinita D. Gupta, is the CEO. [citation needed]He has a bachelor's degree in chemical engineering from the University Department of Chemical Technology, Mumbai, and an MBA from the Wharton School, University of Pennsylvania, U.S. in 2002, [3] [1] where he specialized in healthcare, strategic management ...
IPA was founded in August 1999 by Dilip G Shah and six Indian drugmakers: Cipla, Dr. Reddy's, Lupin, Piramal, Ranbaxy, and Wockhardt. [1] IPA was founded to promote the cause of generic drugs in India [2] and has since expanded to include 24 domestic pharmaceutical companies. [3] Sudarshan Jain is the current secretary general of the IPA. [4]